PRC-063 oral capsules
DrugDaily dose
NCT Number: NCT03172481
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.
Looking for future studies?
Notify Me6 year–12 year
All sexes
Interventional
Phase 3
AVIDA Inc., Newport Beach, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily dose
Daily dose
Time frame: Full-day Classroom - 13 hrs
The SKAMP rating scale is a validated tool that assesses behavioral symptoms of ADHD in a classroom setting. The SKAMP-C comprises 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13), and is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0 = none, 6 = maximal impairment), for a total possible combined score of 0 to 78 (lower score indicated fewer ADHD symptoms). During the Full-day Classroom visit, SKAMP-C was assessed at pre-dose and approximately 1, 2, 4, 6, 8, 10, 12, and 13 hours post-dose. Average post-dose score and change from pre-dose score were analyzed on the individual SKAMP-C scores.
Purdue Pharma, Canada
Industry
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Children (6-12 Years of Age) With ADHD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06626750
ADHD, Attention Deficit Disorder with Hyperactivity
Miami, Florida, United States
View Trial DetailsNCT04082234
ADHD, Attention Deficit Disorder with Hyperactivity
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05796427
ADHD, Attention Deficit Disorder with Hyperactivity
Chicago, Illinois, United States
View Trial DetailsNCT05119660
ADHD, Attention Deficit Disorder with Hyperactivity
East Providence, Rhode Island, United States
View Trial Details